Skip to Main Content

Paper Details

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Journal of Clinical Oncology
16
2022
614D, B.1, B.1.351, B.1.617, Beta, COVID-19 mRNA, CoV-2 614D, Lung Cancer, NSCLC, Omicron, Omicron variant, Patients, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 mRNA, cancer, immunoglobulin G, mRNA, non-small-cell lung cancer, patients, programmed death-1
Author NameAffiliation
Lilin LaiEmory University School of Medicine
Lilin Lai
Lilin LaiCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine
Andreas WielandEmory University School of Medicine
Andreas WielandEmory University
Andreas WielandThe Ohio State University
Andreas WielandPelotonia Institute for Immuno-Oncology, The Ohio State University
Mehul S SutharEmory University School of Medicine
Mehul S Suthar
Mehul S SutharCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Emory University School of Medicine
Rafi AhmedEmory University School of Medicine
Rafi AhmedEmory University
  • 1 - 12

Datasets

Release 1.2